Identification of disulfiram as a secretase-modulating compound with beneficial effects on Alzheimer’s disease hallmarks

Sven Reinhardt¹, Nicolai Stoye¹, Mathias Luderer², Falk Kiefer², Ulrich Schmitt¹, Klaus Lieb¹ & Kristina Endres¹

ADAM10 is a metalloproteinase acting on the amyloid precursor protein (APP) as an alpha-secretase in neurons. Its enzymatic activity results in secretion of a neuroprotective APP cleavage product (sAPP-alpha) and prevents formation of the amyloidogenic A-beta peptides, major hallmarks of Alzheimer’s disease (AD). Elevated ADAM10 levels appeared to contribute to attenuation of A-beta-plaque formation and learning and memory deficits in AD mouse models. Therefore, it has been assumed that ADAM10 might represent a valuable target in AD therapy. Here we screened a FDA-approved drug library and identified disulfiram as a novel ADAM10 gene expression enhancer. Disulfiram increased ADAM10 production as well as sAPP-alpha in SH-SYSY human neuronal cells and additionally prevented A-beta aggregation in an in vitro assay in a dose-dependent fashion. In addition, acute disulfiram treatment of Alzheimer model mice induced ADAM10 expression in peripheral blood cells, reduced plaque-burden in the dentate gyrus and ameliorated behavioral deficits. Alcohol-dependent patients are subjected to disulfiram-treatment to discourage alcohol-consumption. In such patients, enhancement of ADAM10 by disulfiram-treatment was demonstrated in peripheral blood cells. Our data suggest that disulfiram could be repurposed as an ADAM10 enhancer and AD therapeutic. However, efficacy and safety has to be analyzed in Alzheimer patients in the future.

Alzheimer’s disease is the most prevalent dementia in the aging population. With up to 15 million cases worldwide it represents a disease with high impact on medicinal care burden and patient numbers are estimated to increase further in the following years (e.g.1). The fact that the majority of diagnosed Alzheimer cases represent the sporadic, non-genetic form of the disease emphasizes why successful treatment has remained elusive. The origin of the sporadic form still remains enigmatic, hampering a targeted therapy in humans (reviewed in2). One of the pivotal hallmarks of the neurodegenerative process is the production, oligomerization, deposition, and degradation of the Amyloid-beta (A-beta) peptide (see3). This has led to numerous therapeutic approaches, targeting single steps of A-beta metabolism which so far failed (for an overview on recent clinical trials 4). An alternative to such mono-functional drugs might be offered by drugs that interfere with several pathways associated with the disease, therefore acting as multifunctional drugs (for example5–7).

Two proteases compete for cleavage of APP: ADAM10 (A disintegrin and metalloproteinase 10) and BACE-1 (beta site APP cleaving enzyme-1). Shifting the balance toward the alpha-secretase ADAM10 not only prevents generation of neurotoxic A-beta peptides but simultaneously increases levels of the soluble APP fragment sAPPs-alpha in vivo.10-12. The latter has been shown to be neuroprotective and to enhance bouton density in the brains of intracranially infused mice13. Elevating ADAM10 resulted in increased learning and memory of AD model mice and strongly diminished plaque deposition14, while a reduction in BACE-1 levels also rescued AD phenotypes15,16. Manipulating the interplay between both of these proteases has been suggested as an attractive potential target in therapy development16,17. If such a drug could also interfere in a beneficial manner with other pathways contributing to AD – such as hyperphosphorylation of the cytoskeleton-associated protein Tau

¹Department of Psychiatry and Psychotherapy, University Medical Center of the Johannes Gutenberg University, Mainz, Germany. ²Central Institute of Mental Health (CIMH), Department of Addictive Behavior and Addiction Medicine, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany. Correspondence and requests for materials should be addressed to K.E. (email: Kristina.endres@unimedizin-mainz.de)
by glycogen synthase kinase 3 beta (GSK3beta)\(^{18}\) – this might be of high interest. To identify such novel drug candidates for AD treatment, we performed an initial screening of more than 600 FDA-approved drugs to identify candidates regulating transcriptional activity of both genes. We identified disulfiram as one of the most promising candidates and evaluated it further in cells and in mice, as well as in an observatory clinical study. In this study advantage was taken of the fact that alcohol-dependent patients are often given disulfiram to discourage the consumption of alcohol. The so-called disulfiram-ethanol reaction is due to increased serum acetaldehyde concentrations resulting from lack of clearance via aldehyde dehydrogenase, one of the enzymes that are blocked by disulfiram. The discomfort associated with this syndrome (nausea, sweating, chest pain etc.) is intended to serve as a discouraging stimulus. The use of disulfiram in this clinical indication facilitated measurements of ADAM10 expression within peripheral blood cells in humans before and after two weeks of treatment with the newly identified drug.

**Results**

**Identification of disulfiram as an alpha-secretase enhancer from a FDA-approved drug library.** In previous studies, identification of novel ADAM10 enhancers from phytomedical collections via reporter gene assay has been demonstrated to be a promising approach\(^{19,20}\). By analyzing drugs already approved by the FDA, rapid translation into clinical studies is likely, enhancing the attractiveness of such re-purposing strategies. Here, a library of 640 FDA-approved drugs was tested for potential influence on ADAM10 and BACE-1 transcriptional activity in neuronal cells. A non-toxic dosage for human, neuronal SH-SY5Y cells was assessed by starting from a 1:3064 dilution with subsequent dilutions for compounds that resulted in >80 or <20% of viability after 48 h of incubation (see Fig. 1a for the initial results, table with final concentrations: Suppl. Table 1).

The initial dilution was chosen to reach a final concentration of 2 \(\mu\)M for acitretin, which served as an internal ADAM10-inducing control\(^{21}\). 627 out of 640 tested substances were found to be applicable for further testing.

Figure 1. Screening of a FDA-approved drug library for inducers of ADAM10 promoter activity enhancers. (a) SH-SY5Y cells were incubated for 48 h with 0.1% v/v substance and viability assessed using the Cell Titer Glo assay. DMSO (solvent) served as control and values obtained for solvent-treated cells were set to 100%. Dashed lines indicate the maximum tolerated proliferative or toxic effect. Concentrations were subsequently adjusted by further dilution until no toxic/proliferative effect could be observed. 13 substances were excluded from further analyses due to their remaining toxic potential (for final conc. see Suppl. Table 1). (b) SH-SY5Y cells were transiently transfected with a dual reporter vector for both promoter activities, human ADAM10 and BACE-1 (20). Subsequently, cells were incubated with the respective drug or DMSO as a solvent-control (values set to 100%). The experiment was conducted three times independently (SDs are not shown for clarity of the graph). The main part of the tested drugs remained without effects (dark grey box) while a small number of drugs revealed promoter inducing potential (light grey box). The most promising candidate, i.e. high ADAM10 promoter activity and low BACE-1 promoter activity (disulfiram), is indicated by an arrow.
ADAM10 promoter activity to 168% of control but also decreased BACE1 promoter activity to 53% of control (ratio: 3.17). We further investigated the potential of disulfiram as a novel AD drug candidate. Disulfiram shifts APP processing toward the non-amyloidogenic pathway in neuronal cells. Disulfiram was tested in the screening at a concentration of 2.2 \( \mu \text{M} \). Further analysis indicated that concentrations higher than 5 \( \mu \text{M} \) induced cytotoxicity (data not shown). Therefore, drug concentration in the cell culture experiments was restricted to a maximum of 5 \( \mu \text{M} \). We first demonstrated dose-dependency of disulfiram-evoked increase in ADAM10 transcriptional activity by treating SH-SY5Y cells transfected with an ADAM10 promoter-reporter vector with different concentrations of disulfiram (Fig. 2a). While the empty control vector did not respond to disulfiram in any tested concentration, disulfiram increased ADAM10 promoter activity gaining significance for 0.22, 2.2 and 5 \( \mu \text{M} \). This dose-dependent increase was also observed for the murine Adam10 promoter reporter although the results were only significant for concentrations of 2.2 \( \mu \text{M} \) and 5 \( \mu \text{M} \) (Fig. 2b).

Effects observed in promoter reporter assays can yield false positives due to the fact that an isolated DNA sequence is analyzed in the absence of the physiological environment and proper chromosomal location. Therefore, the impact of disulfiram on endogenous ADAM10 protein levels in SH-SY5Y cells was analyzed. Already with the lower concentration of 0.022 \( \mu \text{M} \), ADAM10 protein amount was significantly elevated (Fig. 2c and d, the sum of proform and mature form is presented). This also led to increased amounts of sAPP-alpha (185% of control) while APP full-length protein was not affected. The finding of elevated ADAM10 activity was also confirmed by measuring directly enzymatic activity in cell lysates of SH-SY5Y cells treated for 48 h with...
disulfiram using a pro-fluorescent peptide substrate (Fig. 3a). ADAM10 activity in drug-treated cells nearly was two-fold higher than activity in solvent-treated cells. In addition to ADAM10, ADAM17 (also designated as tumor necrosis factor alpha cleaving enzyme, TACE) can act as an alpha-secretase and lead to elevated sAPP-alpha levels (Endres et al., 2003). Moreover, peptide substrates in commercial enzyme activity kits do not always show perfect specificity. The protein level of TACE was thus analyzed after disulfiram-treatment: no difference could be observed in solvent- and in drug-treated SH-SY5Y cells (Fig. 3b,c; p = 0.9). For the beta-secretase BACE-1 a down-regulation was observed in the initial dual promoter assay and could also be confirmed in a single promoter reporter vector for human BACE-1 (data not shown). Analysis of BACE-1 protein and its cleavage product sAPP-beta revealed reduction which was not statistically significant (Fig. 3b,c). Nonetheless, a reduction of A-beta peptides of about 20% as compared to solvent-treated cells was achieved by 48 h treatment with disulfiram (Fig. 3d). Neuronal cells treated with synthetic A-beta 42 peptides exhibited a diminished viability as shown in Fig. 3e. Co-treatment with disulfiram over a time period of 48 h was able to reverse this toxic effect and such cells were indistinguishable from control-treated cells (p = 0.65).

We next addressed potential mechanisms of disulfiram-mediated increase of ADAM10. Interestingly, ADAM10 can be activated by dopaminergic agonists22. As disulfiram is a known inhibitor of dopamine-beta-hydroxylase, this might explain the increase in ADAM10 expression. Dopamine would be expected to accumulate with disulfiram-treatment while norepinephrine levels should decrease (Fig. 4a). SH-SY5Y cells are a suitable model to investigate this hypothesis, as these cells have been described to exhibit functional dopamine metabolism (reviewed in23). However, when SH-SY5Y cells were incubated with increasing amounts of dopamine the activity of the human ADAM10 promoter was reduced by about 40% as compared to control (100 µM dopamine, Fig. 4b). Incubation with norepinephrine resulted in a statistical significant increase of reporter gene activity to 125% of control for 5 µM while all other tested concentrations remained without effect. This result strongly suggests the effect of disulfiram on ADAM10 gene expression is independent of dopamine metabolism.

Figure 3. Disulfiram selectively increases ADAM10 expression and leads to decrease in A-beta production. SH-SY5Y cells were incubated with disulfiram at a concentration of 2.2 µM, or DMSO as a solvent-control (values set to 100%) for 48 h. (a) The cell lysate was used for measurement of ADAM10 activity by using a pro-fluorescent specific substrate. Additionally, aliquots of cell lysate were subjected to SDS-PAGE and Western blotting for analysis of levels of TACE and BACE-1. GAPDH served as a loading control. Soluble proteins from cell supernatants after 5 h of secretion were precipitated by trichloroacetic acid and subjected to SDS-PAGE and Western blotting with a sAPP-beta specific antibody (b). All measured densitometric values were normalized to values obtained for GAPDH of the respective sample (c) (n ≥ 5 for all quantifications). For TACE, the sum of mature and proform was quantified. Cropped blot pictures are separated by a white space, for full-length blot pictures please see Suppl. Figure 2. A-beta peptide secretion (A-beta 1-x) was measured by ELISA in samples from a 16 h secretion period (d). Statistical analysis: unpaired Student’s t-test (**p < 0.001; *p < 0.05; ns, p > 0.05). (e) Cells treated for 48 h with solvent (control), human A-beta 42 peptides or peptides in combination with disulfiram (A-beta/Dis) were analyzed for viability (n = 15, two independent experiments). Statistical analysis: One Way ANOVA ***p < 0.001; ****p < 0.0001).
In a further assessment of the effects of disulfiram on aspects of AD pathogenesis, we found that disulfiram inhibited the aggregation of A-beta \textit{in vitro} with 1 and 2 \( \mu \)M (Fig. 4b). Moreover, with 2.2 and 5 \( \mu \)M disulfiram an inhibition of Tau-kinase GSK3beta was seen \textit{in vitro} (Fig. 4c). This in sum indicates that disulfiram might have the potential for being a multifunctional therapeutic compound with both, potential to prevent amyloidogenic aggregation as well as over-activation of Tau kinase.

**ADAM10-enhancing properties of disulfiram in AD model mice.** To ascertain whether disulfiram also exhibits therapeutic potential \textit{in vivo}, Alzheimer model mice (5xFAD) were treated for two days with the drug (52 mg/kg per day). This represents the human equivalent dosage (HED) calculated as described previously\textsuperscript{24} for a daily dosage of 250 mg in an adult weighing 60 kg (maintenance dose in alcohol dependent patients: 200 to 500 mg/day). Using the full HED, resulted in gastrointestinal difficulties in the mice (diarrhea, apathy, changes in gut tissue) and therefore it was decided to reduce the daily dosage to 26 mg/kg. This abolished undesired side effects and mice showed no signs of gastrointestinal impairment (see also Suppl. Figure 3). After two days of treatment with this comparably low dose, no increase of Adam10 mRNA in the brain was observed on the third day (Fig. 5a). Interestingly, Adam10 mRNA quantitation in blood cells revealed a disulfiram–dependent induction to 123\% of control-treated animals. This was accompanied by decreased amounts of Bace-1 mRNA levels (60\% of control; Fig. 5b) that were also only observed in blood but not in brain. This could indicate that the mechanism of regulation observed in cell culture experiments is different to that in the murine brain, that mRNA kinetics do not allow detection of elevated Adam10 and decreased Bace-1 mRNA 24 h after the last injection, or that disulfiram was administered in too low a concentration. In order to understand whether disulfiram is able to penetrate the
brain in sufficient amounts and if it was systemically effective, zinc concentrations in brain tissue and in urine were measured. The chelator disulfiram should lead to an increase of its urinary excretion (in analogy to data on nickel\textsuperscript{25}). Zinc levels remained relatively unaffected within the brain (Fig. 5c). However, urinary excretion of zinc was drastically elevated to about 300% of control animals. Therefore, disulfiram acts in a systemic manner: however, its concentration within the brain might have been too low or its effect might already have been reversed due to chemical conversion\textsuperscript{26} at the chosen time-point of investigation (24 h after the last injection). Because the half-life time of the Adam10 protein is rather long (72 h\textsuperscript{27}) and increased amounts of the enzyme might still persist 24 h after the last drug administration, we nevertheless decided to analyze its catalytic activity in brain tissue: Adam10 activity was nearly doubled in brain material derived from disulfiram-treated mice as assessed by a pro-fluorescent substrate cleavage assay (Fig. 5d). Moreover, the amount of soluble A-beta\textsubscript{42} peptides was found to be decreased (Fig. 5e) although not reaching statistical significance in the small group of investigated animals.

To assess potential pathomechanistic relevance of disulfiram-treatment in the Alzheimer mouse model brain slices of mice treated by two daily injections of disulfiram (26 mg/kg/day) were stained for A-beta depositions with antibody 6E10 (Fig. 6a I). Representative cortical regions and subiculum displayed only non-significant decrease in staining signals that represent oligomeric as well as plaque-deposited A-beta peptides. The dentate gyrus, on the contrary, showed a reduced staining intensity and plaque number in mice treated with disulfiram (Fig. 6a II and b; 71% of control).

We conducted two behavioral tests that rely on hippocampal integrity\textsuperscript{28,29} to investigate a potential beneficial effect of the short-term treatment with disulfiram on the AD model mice. In the nest building test, 5xFAD mice showed an impaired performance as compared to wild type mice as indicated by a lower score and higher amount of nesting material which was not incorporated in the nest (Fig. 6c; both mouse groups, wt and control, were injected with the solvent). AD model mice treated with disulfiram showed significantly increased nest building ability as measured by the score and amounts of integrated nesting material as compared to solvent-treated AD model mice. Additionally, the impairment of the 5xFAD mice observed in the novel object recognition test (Fig. 6d) in comparison to wild type mice was totally rescued upon treatment with disulfiram.

**Induction of ADAM10 in blood cells by clinical treatment with disulfiram.** Disulfiram is used in alcohol dependent patients as a relapse-preventing treatment. This allows an analysis in a natural clinical setting of the capacity of disulfiram to induce ADAM10 in human peripheral blood cells (for demographics see Fig. 7a).
Blood was sampled at two time points: before the start of treatment (baseline) and after approximately two weeks (17 ± 3 days) of treatment. As stability of ADAM10 expression in blood cells over time has not been investigated so far to our knowledge, we also included a healthy control group without treatment and analyzed ADAM10 expression over a time frame of two weeks. While most healthy subjects displayed an unaltered ADAM10 expression, the vast majority of the disulfiram-treated patients showed an increase of levels of ADAM10 mRNA (Fig. 7b). Induction of ADAM10 in humans in peripheral tissue by disulfiram treatment is thus feasible but efficacy and safety has to be tested in AD patients in the future.

Discussion

Development of novel drugs for the treatment of Alzheimer’s disease has to face a variety of challenges such as late-life disease diagnosis, lack of well-understood therapeutic targets and additionally penetrance of the blood brain barrier. Drug re-purposing may offer an important strategy to accelerate process (as shown in30). As an example, the cancer drug AM-80 has been demonstrated to contribute beneficial therapeutic value in AD model mice31,32. However, efficacy in human patients has always to be verified because most AD model mice rely on genetic manipulation and inadequately represent the typical patient suffering from sporadic AD. In the case of acitretin, a drug prescribed for psoriasis33, we showed that it is not only an ADAM10 inducer in cell culture and mice, but also has a positive effect in mild to moderately affected human patients21,34. Here, we took an unbiased approach and analyzed a library of FDA-approved drugs for their potential to enhance ADAM10 expression. We identified disulfiram as one of the most promising candidates, resulting in lowering of BACE-1 promoter activity but also an increase in ADAM10 promoter activity. This is important as drugs that only aim at reducing A-beta peptide levels failed to show therapeutic effects in clinical trials published to date. Increasing the amount of sAPP-alpha might be a more reliable therapeutic strategy as this protein fragment has been shown to exert neurotrophic and neuroprotective properties in many publications. For example, recombinant sAPP-alpha protected primary hippocampal neurons from cell death via activation of the Akt-survival pathway35.

To our surprise, treatment of the 5xFAD Alzheimer model mice with disulfiram did not elevate Adam10 mRNA levels in the brain, although the murine Adam10 promoter, similar to the human promoter, could be induced by the drug in cell culture experiments. However, the intensity of the increase in promoter activity was much lower for the murine gene than for the human and the response necessitated higher drug concentrations.
Measurement of the zinc chelating property of disulfiram in mouse brain tissue demonstrated no change of the zinc concentration within the brain parenchyma as a result of the treatment, while the urinary excretion was significantly increased. It is thus possible that the effective concentration of disulfiram in brain is insufficient to increase Adam10 expression in spite of the observed increase in Adam10 levels in blood. One of the metabolites of disulfiram, N-acetyl-S-(N,N-diethylcarbamoyl) cysteine (DETC-NAC), could be detected in the nucleus accumbens and the medial prefrontal cortex of rats treated with 200 mg/kg disulfiram intraperitoneally. However, the concentration reached in these brain areas was much lower (1.1 and 2.5 nM) compared with plasma levels (80 nM) 6 h after application. The injected concentration used in the study presented here was much lower to avoid toxic effects and possibly insufficient to increase Adam10 transcriptional activity in the brain. Additionally, measurement of mRNA levels was conducted 24 h after the last injection and disulfiram is – due to the instability of its disulfide bond – is highly reactive and therefore subjected to fast degradation. Nevertheless, an increase of Adam10 activity as well as a tendency for reduced soluble A-beta peptide levels could be demonstrated in the brain of 5xFAD mice treated with disulfiram. An effect on the proteases Adam10 and Bace-1 might indeed have occurred but was only visible at the protein level due to the relative long stability of the protein in contrast to the stability of the respective mRNAs. In peripheral blood cells, however, the ratio of Adam10 and Bace-1 mRNA was affected in favor of Adam10. Besides the assumed beneficial effect in brain, ADAM10 has been reported to produce a truncation product of Trx1, thioredoxin 80 (Trx80), from monocytes. This blood-derived proteolysis product has been detected in human brain and seems to be protective against aggregation of A-beta peptides. This fact, together with the in vitro observed aggregation-inhibiting property of disulfiram and its influence on Adam10 activity might be sufficient to explain the observed reduction in 6E10-positive staining within the dentate gyrus of the mice and the resulting increase in behavioral performance in two tasks that at least partly depend on hippocampal function. Nevertheless, we cannot exclude that additional effects on the immune system, on mitochondrial function or on other relevant molecules contribute to the beneficial outcome. For example, our own study revealed that disulfiram has the capability to lower GSK-3β activity in vitro which might result in altered Tau posttranslational modification also in vivo.

Along with the clinical use of disulfiram in the treatment of alcohol dependence, side effects of cognitive performance such as drowsiness, impaired attention and memory impairment have been described. In addition, cases of psychosis have been associated with high dosage in alcohol dependent patients. An early investigation on intellectual function of patients treated with disulfiram reported no impairment, while Prigatano and colleagues demonstrated a reduced improvement in neuropsychological functioning in disulfiram-treated patients versus a milieu treatment program group three weeks after acute alcohol detoxification. In sum, disulfiram might act as a deleterious substance on cognitive functioning in the context of alcohol abuse and patients with increased vulnerability (personal or familial antecedents of psychosis). However, in healthy prisoner volunteers, high dosage of the drug (0.5 g/day to 1.5 g/day) also resulted in impaired immediate memory and e.g. color naming. Using a more typical dosage of 0.5 g/day, Peeke and colleagues reported in non-alcoholic volunteers over two weeks on a psychological test battery very few significant differences between baseline and disulfiram-treated sessions. Interestingly, these were in the opposite direction to that expected and demonstrated improvement under disulfiram-medication (DSS task, 

Figure 7. Longitudinal ADAM10 mRNA measurement in untreated healthy controls and in alcohol addicted patients treated with disulfiram. (a) Two groups of subjects were included in the investigation: healthy controls and alcohol dependent subjects. Both groups were matched for age and smokers rate. The gender rate differs significantly between the groups but represents normal ratios found in the healthy as well as the alcohol dependent part of the population. The alcohol dependent subjects were treated with disulfiram following the normal treatment schedule of the clinical centres (Department of Psychiatry and Psychotherapy, Mainz or CIMH, Mannheim). From both groups blood was sampled by venipuncture on day 1 and approx. 17 days later. One patient was excluded from the investigation due to lack of compliance and extremely extended time point for the second blood draw (3 months). (b) ADAM10 mRNA level was quantified from total RNA preparations in healthy controls and alcoholic dependent patients treated with disulfiram and is presented as the ratio between values obtained after ca. two weeks and at baseline (RNA amount was normalized to PGK-1 RNA levels). Mean and SEM are indicated. Statistical analysis: unpaired Student’s t-test (*p < 0.05).
confusion assessment46). Predicting a beneficial outcome for Alzheimer patients under therapy with disulfiram thus remains difficult, even in the light of the encouraging data from the mouse model. In regard to the clinical study presented here, it also has to be considered that stability of ADAM10 over the two weeks of investigation in untreated condition has only been demonstrated in healthy controls. In the alcohol-dependent patients treated with disulfiram, the pre-post-comparison revealed an increase of ADAM10 expression. However, it cannot be excluded that the condition of non-alcohol intake enforced by disulfiram alone might also affect ADAM10 levels. Another aspect to be considered are the effects on the cholinergic system that have been reported for disulfiram, for example effects on the autonomous nervous system in rodents. A decrease in the histochemical reactivity for acetylcholine-esterase was observed in the nerve plexuses of the gut wall in rats treated with 220–580 mg/kg for 1–3 weeks47. In the treatment presented here which included a paradigm with lower dosage, no significant changes in acetylcholine-esterase levels in gut or brain tissue were observed (shown in Suppl. Figure 3).

Nevertheless, a 15 days treatment of rats with disulfiram, even at low doses (50 mg/kg/day) showed a selective elevation of acetylcholine in the hippocampus of the animals48. The assumption that acetylcholine deficit is one of the major drivers of cognitive decline in Alzheimer’s disease underpins the clinical treatments used today for Alzheimer patients, namely acetylcholine esterase inhibitors such as Donepezil (e.g. reviewed by49,50). In our study we did not test the release or synthesis of acetylcholine, but such an effect could clearly contribute to the observed amelioration of cognitive deficits. Such an add-on effect might also be contributed by effects on structural properties of the amyloid precursor protein or its cleavage products. It has been shown that sAPP-alpha production increased upon disulfiram application by inhibiting dimerization of the APP ectodomain in 7W-CHO non-neuronal cells51. In addition, Nagai and Ito reported that inhibition of hydrogen peroxide production via disulfiram attenuated the increase in Abeta1–42 in the lens capsule-epithelium of a rat cataract model52.

In conclusion, disulfiram may influence AD pathology in multiple ways, resulting in an increase of functional behavior at least in mice at low doses. Low compliance by demented patients can be partially circumvented as disulfiram can be administered by subcutaneous implantation53. Development of novel encapsulated or nanoparticle-assisted forms of the drug54,55 might additionally help in the establishment of a potential therapy. However, safety in AD patients and impact on cognition have to be investigated in the future.

Materials and Methods

Material. The FDA approved drug library (Enzo) was kept at −80 °C. Aliquots were prepared on clear 96 well plates using the Liquidator (Qiagen). Disulfiram for further analyses was purchased from Sigma.

Cell culture. The human cell line SH-SY5Y was maintained at humidified air (95%), 5% CO₂, 37 °C, and cultured in DMEM/F12 (Life Technologies, Darmstadt, Germany) supplemented with 10% FCS and 1% Glutamine (GE Healthcare, Piscataway, NJ, USA).

Toxicity assay. Cells were seeded at a density of 45 000 cells per well of a white glass-bottom 96 well plate (Greiner Bio-OneGmbH, Frickenhausen, Germany) in OptiMEM (Life Technologies, Darmstadt, Germany) and incubated with the substances of the FDA-approved library. Cell viability was assessed using the Cell Titer Glo Assay (Promega). Concentrations that were found toxic (decrease in viability of >20% in comparison to solvent control) or pro-proliferative (increase in viability >20%) were reduced until appropriate.

For measuring a potential protective effect of disulfiram on A-beta treatment of cells, SH-SY5Y cells were seeded at a density of 38 000 cells per well of a 96 well plate (Greiner Bio-OneGmbH, Frickenhausen, Germany) in culture medium supplemented with solvent (DMSO), human A-beta42 peptides (2.5 µM, Anaspec) or peptides combined with 2.2 µM disulfiram for 48 h. Subsequently, MTT reagent was added (5 µl of 5 mg/ml stock solution) and viability assessed as described before56.

Reporter gene assay. The dual luciferase reporter assay was performed as described previously57. In brief, a reporter vector was used for simultaneously detecting human BACE-1 promoter activity and human ADAM10 promoter activity with the dual luciferase reporter kit (Promega). Concentrations that were found toxic (decrease in viability of >20% in comparison to solvent control) or pro-proliferative (increase in viability >20%) were reduced until appropriate.

Western blotting. Cells were seeded on 12-well plates at a density of 500 000 per well and incubated with the substances as indicated for 48 h. Cell supernatant from a 5 h secretion period was collected and soluble proteins precipitated via TCA58. Cells were harvested in PBS, protein content determined, and half of the supernatant or 20 µg proteins subjected to SDS polyacrylamide gel electrophoresis. Proteins were blotted onto nitrocellulose and blocked with 0.2% I-Block (Thermo Fisher Scientific) solution including 0.05% Tween20. Primary antibodies were as follows: ADAM10 rabbit polyclonal antibody (Merck, Darmstadt, Germany), ADAM17 rabbit polyclonal antibody (Chemicon, Merck), BACE-1 rabbit monoclonal antibody (D10E5, Cell Signaling Technology, Danvers, MA, USA), APP N-terminal mouse monoclonal antibody (for detection of sAPP-alpha, 6E10, Covance, Madison, WI, USA), anti-sAPP-beta (Covance, Madison, WI, USA) or APP C-terminal antibody58. As a loading control, GAPDH was detected (14C10, Cell Signaling, Danvers, MA, USA). Blots were incubated with respective secondary antibody coupled with horseradish peroxidase (Thermo Scientific, Karlsruhe, Germany) and signals obtained by applying SuperSignal West Femto chemiluminescent substrate (Thermo Scientific, Karlsruhe, Germany) were captured using a CCD-camera imaging system (Raytest, Straubenhardt, Germany).
**Amyloid-beta aggregation assay.** The amyloid aggregation assay was conducted in 50 mM Tris/150 mM NaCl (pH 7.2) supplemented with 125 μM Thioflavin T (Sigma) and 0.1 mg/ml human Aβ42-amyloid (1–42) (Anaspec) in black 384 well plates. Fluorescence was measured in a Fluostar Omega (BMG Labtech, Cary, NC, USA) (Ex/Em = 440/484 nm) to analyze Aβ-aggregation.

**GSK3-beta activity assay.** The luminescent GSK3-beta assay was performed as recommended by the vendor (Promega).

**Animals.** Male 5xFAD mice (Jackson Lab) were crossbred with C57BL/6 J female mice for maintenance. Non-transgenic female offspring was used as control. All animals were group-housed in cages in a 12 h light/dark cycle with food and water available ad libitum unless otherwise stated (three to five animals/cage). All procedures were performed in accordance with the European Communities Council Directive regarding care and use of animals for experimental procedures and were approved by local authorities (Landesuntersuchungsamt Rheinland-Pfalz; approval number G14-1-087).

**Disulfiram treatment.** Mice aged 3 months were assigned randomly into the control group (solvent, DMSO) or the disulfiram group (26 mg/kg per day). Disulfiram (stock solution of 100 mg/ml, kept in aliquots at −20 °C) was diluted freshly in DMSO to 0.8 mg/150 μl injection solution. Animals were injected i.p. at a fixed time in the morning of two consecutive days.

**Behavioral procedures.** For the assessment of nest building capability, animals were single-caged and habituated to the nesting material used for scoring (Sizzle Pet Nesting Material, Claus GmbH, Germany; 10 g per cage) for 24 h in the presence of their former nest building material (paper towel). Animals then received fresh nesting material for three days. Subsequently, animals were deprived for 24 h to enhance nest building motivation and also received their first injection. On day six, mice were injected the second time and cages were supplemented with fresh nesting material to allow nest building for overnight. The following morning, quality of the nest was scored as described by Deacon59 (e.g. 0: no nest built; 5: perfectly closed dome built). Additionally, the nesting material that has not been introduced into the nest was weighed.

For the novel object recognition (NOR) test, mice were injected on day one and two. On day two they were additionally habituated for 6 min to the Y-maze which was used for the NOR test. On the third day, mice were represented in a first session for 6 min to two identical objects in two arms of the Y-maze. Two hours later, one of the objects was replaced by a novel object and mice allowed to explore the maze for another 6 min. A computerized video system registered moving-path and presence in the defined areas (non-displaced (NDO) and displaced object (DO)) automatically (hardware consisted of an IBM-type AT computer combined with a video digitizer and a CCD video camera). The software used for data acquisition and analysis was EthoVision XT release 8.5 (Noldus Information Technology, Utrecht, Netherlands). Analysis of the data was performed using the discrimination index (time (DO-NDO)/ time (DO + NDO)).

**Clinical study.** Human healthy controls and patients were recruited from the Clinic of Psychiatry and Psychotherapy (Mainz) or from the CIMH (Mannheim). Exclusion criteria for the patients were a diagnosed Alzheimer dementia and a treatment with disulfiram less than four weeks before baseline assessment. Patients were included that were treated with disulfiram for alcohol relapse prevention. Exact treatment schedule was chosen by the medicating physician. In general, a dosage of 1500, 1000 and 500 mg is used for the first three days, and then a dose of 500 mg three times a week is prescribed. Patients that were compliant for 14 days were included in the study. All patients gave informed consent for study participation; the study has been approved by local authorities (Landesärztekammer Rheinland-Pfalz), and is registered with clinical trials.gov (NCT03212599). All experiments were performed in accordance with relevant guidelines and regulations.

**Tissue dissection and sample collection.** Mice were anaesthetized with isoflurane and sacrificed by decapitation. Truncal blood was mixed with RNA later (Qiagen, Hilden) and urine was collected. One brain hemisphere was drop fixed in 4% formaldehyde for IHC and the other hemisphere immediately cut in cubes and submerged in RNA later for preservation or snap frozen for zinc measurements and assessment of Acetylcholine esterase levels by the method of Ellman (see Suppl. Figure 2). In addition, sections of the gut were taken to assess Acetylcholine esterase levels. All samples were stored at −80 °C before usage despite IHC samples. For human blood, samples were collected in a 2.5 ml EDTA monovette (Sarstedt, Nümbrecht, Germany), inverted three times, stored upright and processed within maximal 20 minutes after puncture. 0.5 ml blood was pipetted to 1.3 ml RNA later and mixed by inverting. Samples were stored at −80 °C before further use.

**Zinc quantitation.** Snap frozen hemispheres were grinded manually under nitrogen cooling and 1 mg material suspended in water used for assessment of zinc amount with the fluorogenic zinc quantification kit (Abcam). Values were corrected for background fluorescence calculated as ng/mg tissue wet weight. Urine was used undiluted and obtained values corrected for autofluorescence.

**A-beta ELISAs.** SH-SY5Y cells were seeded on 12 well plates at a density of 500 000 cells per well and medium was exchanged 5 h after passage with medium containing 2.2 μM disulfiram or solvent (DMSO). 24 h later, cell supernatant was exchanged by 1 ml fresh drug-containing medium per well and secreted proteins were collected for 1h. 200 μl of cell supernatant were subjected to human Aβ 1-x ELISA as recommended by the vendor (IBL).
Brain tissue grinded under nitrogen cooling was suspended in extraction buffer (100 mg/800 μl; 10 mM Tris HCl pH 7.4; 100 mM NaCl, 1% TritonX100, 0.1% SDS, 1 mM EDTA, Protease-Inhibitor without EDTA (RocheMini complete)) and homogenized with a tissue mill (TissueLyzer, Qiagen, Hilden, Germany) and stainless steel beads (5 mm, Qiagen). The suspension was incubated on ice with vortexing every 10 min for 30 min, centrifuged (13 000 g, 4 °C, 10 min) and the supernatant diluted 1:200 in standard diluent buffer of the ELISA kit (Human Aβ25-35, Invitrogen, Camarillo, CA, USA). The assay was performed as recommended by the vendor.

**ADAM10 activity assay.** SH-SY5Y cells were seeded on 24 well plates at a density of 260 000 cells per well and medium was exchanged 5 h after passage with medium containing 2.2 μM disulfiram or solvent (DMSO). After 48 h of incubation, cells were scraped and collected by centrifugation (13 000 g, 4 °C, 3 min). The cell pellet was resuspended in 20 μl assay buffer (AnaSpec) and incubated for 15 min on ice. 8 μl of cell suspension were supplemented with 2 μl DMSO or GM6001 solution in black 384 well plates.

Tissue was prepared as described for A-beta ELISA. The pellet from centrifugation was washed in 200 μl PBS with protease inhibitors. 50 μl of tissue suspension was pelleted (3 min, 3,000 g, 4 °C) and washed two-times in assay buffer provided by the vendor (100 μl, AnaSpec, Seraing, Belgium) with 10 min incubation on ice. 5 μl of tissue suspension was supplemented by 3 μl assay buffer and 2 μl of DMSO or GM6001 solution in black 384 well plates.

For both, cell suspension or tissue lysate, 10 μl of pre-warmed substrate solution were added and kinetics measured by a FluoStarOmega (BMG Labtech; 60 min measurement with measuring every 2 min after orbital shaking, 37 °C). Slopes of fluorescent signal-increase over time as measured by Em485 nm/Exc520 nm for ADAM10 activity assay were calculated and the data was presented as mean ± SEM.

**Plaque analysis.** IHC sections were prepared and stained with anti-APP antibody 6E10 (Covance) as described previously. Two sections per mouse were used for densitometric analysis in a total magnification of 40 × : five areas were determined to be measured as shown in Fig. 6a. All areas were corrected for the value of the background area. For cortical tissue, two distinct areas were analyzed and integrated into a mean value. Experimenters were blinded for the treatment of the mice during analysis.

**Quantitative real-time PCR.** Total RNA was extracted according to the manufacturer’s instructions (RNA II, Qiagen, Hilden). For human and murine blood, RNA was extracted with the RiboPure Blood Kit (Ambion) as recommended by the manufacturer. 20 ng (mouse blood) or 100 ng RNA were used for quantitative Real-time PCR with the QuantiTectSYBRGreen Kit (Qiagen, Hilden) performed in a StepOnePlusCycler (Life Technologies, Darmstadt, Germany). Primers were as follows: Adam10 (QT00106351), Bace-1 (QT00493948), murine 18SrRNA (QT00493948), murine 18SrRNA (QT02448075), ADAM10 (QT00032641), PGK-1 (QT00013776). Levels of mRNA were normalized to the mRNA levels of the house keeping genes (18SrRNA/PKG-1) using a standard curve.

**Statistical analysis.** For comparison of two groups, data were analyzed by Student’s t-test, followed by Bonferroni’s correction. One-way analysis of variance (ANOVA) was performed for three or more groups, followed by the LSD post hoc test. P-values < 0.05 were considered statistically significant and results were represented as mean ± SD (cell culture/in vitro experiments) or ± SEM (animal experiments/clinical study). Data analyses were performed using GraphPad Prism 6 (Graph Pad Software, La Jolla, CA, USA).

**Data availability statement.** The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

**References**

1. Wimo, A. et al. The worldwide costs of dementia 2015 and comparisons with 2010. *Alzheimers Dement* 13, 1–7, https://doi.org/10.1016/j.dalz.2016.07.150 (2017).
2. Dorszewski, J., Prendecki, M., Oczkowski, A., Dezor, M. & Kozubski, W. Molecular Basis of Familial and Sporadic Alzheimer’s Disease. *Curr Alzheimer Res* 13, 952–963 (2016).
3. Hardy, J. The discovery of Alzheimer-causing mutations in the APP gene and the formulation of the “amyloid cascade hypothesis”. *FEBS J* 284, 1040–1044, https://doi.org/10.1111/febs.14004 (2017).
4. Bachurin, S. O., Bovina, E. V. & Ustyugov, A. A. Drugs in Clinical Trials for Alzheimer’s Disease: The Major Trends. *Med Res Rev*, https://doi.org/10.1002/med.21434 (2017).
5. Milelli, A. et al. Tarcire-based Multifunctional Agents in Alzheimer’s Disease: an Old Story in Continuous Development. *Curr Med Chem*, https://doi.org/10.2174/09298671324666170309123920 (2017).
6. Sang, Z. et al. Design, synthesis and evaluation of scutellarein-O-acetamidoalkylbenzylamines as potential multifunctional agents for the treatment of Alzheimer’s disease. *Eur J Med Chem* 135, 307–323, https://doi.org/10.1016/j.ejmech.2017.04.054 (2017).
7. Unzeta, M. et al. Multi-Target Directed Donepezil-Like Ligands for Alzheimer’s Disease. *Front Neurol* 10, 205, https://doi.org/10.3389/fnn.2016.00205 (2016).
8. Lammich, S. et al. Constitutive and regulated alpha-secretase cleavage of Alzheimer’s amyloid precursor protein by a disintegrin metalloprotease, *Proc Natl Acad Sci USA* 96, 3922–3927 (1999).
9. Vasan, R. et al. Beta-secretase cleavage of Alzheimer’s amyloid precursor protein by the transmembrane aspartic protease BACE. *Science* 286, 735–741 (1999).
10. Postina, R. et al. A disintegrin-metalloproteinase prevents amyloid plaque formation and hippocampal defects in an Alzheimer disease mouse model. *J Clin Invest* 113, 1456–1464, https://doi.org/10.1172/JCI28864 (2004).
11. Kuhn, P. H. et al. ADAM10 is the physiologically relevant, constitutive alpha-secretase of the amyloid precursor protein in primary neurons. EMBO J 29, 3020–3032, https://doi.org/10.1038/emboj.2010.167 (2010).

12. Jorissen, E. et al. The disintegrin/metalloproteinase ADAM10 is essential for the establishment of the brain cortex. J Neurosci 30, 4833–4844, https://doi.org/10.1523/JNEUROSCI.2521-09.2010 (2010).

13. Bell, K. F., Zheng, L., Fahrenholz, F. & Cueto, A. C. ADAM-10 over-expression increases cortical synaptogenesis. Neurobiol Aging 29, 554–565, https://doi.org/10.1016/j.neurobiolaging.2006.11.008 (2008).

14. Roberds, S. L. et al. BACE knockout mice are healthy despite lacking the primary beta-secretase activity in brain: implications for Alzheimer’s disease therapeutics. Hum Mol Genet 10, 1317–1324 (2001).

15. McConlogue, L. et al. Partial reduction of BACE1 has dramatic effects on Alzheimer plaque and synaptic pathology in APP Transgenic Mice. J Biol Chem 282, 26326–26334, https://doi.org/10.1074/jbc.M111.127115 (2014).

16. Endres, K. & Deller. Regulation of Alpha-Secretase ADAM10 In vitro and In vivo: Genetic, Epigenetic, and Protein-Based Mechanisms. Front Mol Neurosci. 10, 56, https://doi.org/10.3389/fnmol.2017.00056 (2017).

17. Alonso, A. D., Beharry, C., Corbo, C. P. & Cohen, L. S. Molecular mechanism of prion-like tau-induced neurodegeneration. Alzheimers Dement 12, 1090–1097, https://doi.org/10.1016/j.jalz.2015.12.014 (2016).

18. Schuck, P. et al. Extract of Caragana arganica as a potential therapeutic option for increasing alpha-secretase gene expression. Phytomedicine 22, 1027–1036, https://doi.org/10.1016/j.phymed.2015.08.001 (2015).

19. Meineck, M., Schuck, F., Abdelfatah, S., Effert, T. A. & Endres, K.Identification of Phlogacantholide C as a Novel ADAM10 Enhancer from Traditional Chinese Medicinal Plants. Medicines 3 (2016).

20. Tippmann, F., Hundt, J., Schneider, A., Endres, K. & Fahrenholz, F. Up-regulation of the alpha-secretase ADAM10 by retinoic acid receptors and acitretin. FASEB J 23, 1643–1654, https://doi.org/10.1096/fj.08-121392 (2009).

21. Yoon, S. & Baik, J. H. Dopamine D2 receptor-mediated epidermal growth factor receptor transactivation through a disintegrin and metalloproteinase regulates dopaminergic neuron development via extracellular signal-related kinase activation. J Biol Chem 288, 28435–28446, https://doi.org/10.1074/jbc.M113.461202 (2013).

22. Xie, H. R., Hu, L. S. & Li, G. Y. SH-SY5Y human neuroblastoma cell line: in vitro cell model of dopaminergic neurons in Parkinson’s disease. Chin Med (Engl) 123, 1086–1092 (2010).

23. Reagan-Shaw, S., Nihal, M. & Ahmad, N. Dose translation from animal to human studies revisited. Front Mol Neurosci. 29, 554–565, https://doi.org/10.3389/fnmol.2012.0056 (2015).

24. Deacon, R. M., Croucher, A. & Rawlins, J. N. Hippocampal cytotoxic lesion effects on species-typical behaviours in mice. Behav Brain Res 135, 203–205 (2002).

25. Kim, T. W. Drug repositioning approaches for the discovery of new therapeutics for Alzheimer’s disease. Neurotherapeutics 12, 132–142, https://doi.org/10.1007/s13311-014-0235-7 (2015).

26. Kawahara, K. et al. Oral administration of synthetic retinoid Am80 (Tamibaronete) decreases brain beta-amyloid peptides in APP23 mice. Biol Pharm Bull 32, 1307–1309 (2009).

27. Kawahara, K. et al. Cooperative therapeutic action of retinoic acid receptor and retinoid x receptor agonists in a mouse model of Alzheimer’s disease. J Alzheimer’s Dis 42, 587–605, https://doi.org/10.3233/JAD-132720 (2014).

28. Dogra, S. & Yadav, S. Actinfilin in psoriasis: an evolving scenario. Int J Dermatol 53, 525–538, https://doi.org/10.1111/ijd.12365 (2014).

29. Endres, K. et al. Increased CSF APP-A alpha levels in patients with Alzheimer disease treated with acitretin. Neurology 83, 1930–1935, https://doi.org/10.1212/WNL.0000000000000174 (2014).

30. Milosch, N. et al. Holo-APP and G-protein-mediated signaling are required for sAPPalpha-induced activation of the Akt survival pathway. Cell Death Dis 5, e1391, https://doi.org/10.1038/cddis.2014.352 (2014).

31. Winefield, R. D. et al. N-acetyl-S-(N,N-diethylcarbamoyl) cysteine in rat nucleus accumbens, medial prefrontal cortex, and in rat and human plasma after disulfiram administration. J Pharm Biomed Anal 32, 1307–1309 (2009).

32. Puglielli, L., Ellis, B. C., Saunders, A. J. & Kovacs, D. M. Ceramide stabilizes beta-site amyloid precursor protein-cleaving enzyme 1 and promotes amyloid beta-peptide biogenesis. J Biol Chem 278, 19777–19783, https://doi.org/10.1074/jbc.M300466200 (2003).

33. Gil-Bea, F. et al. Thioedoxin-80 is a product of alpha-secretase cleavage that inhibits amyloid-beta aggregation and is decreased in Alzheimer’s disease brain. EMBO Mol Med 4, 1097–1111, https://doi.org/10.1002/emmm.201201462 (2012).

34. Wilson, A. Disulfiram implantation in alcoholism treatment. A review. J Stud Alcohol 36, 555–565 (1975).

35. Lemere, F. Disulfiram as a sedative in alcoholism. Q J Stud Alcohol 14, 199–197 (1953).

36. Mohapatra, S. & Rath, N. R. Disulfiram Induced Psychosis. Clin Psychopharmacol Neurosci 15, 68–69, https://doi.org/10.9758/cpn.2017.15.1.68 (2017).

37. De Melo, R. C., Lopes, R. & Alves, J. C. A case of psychosis in disulfiram treatment for alcoholism. Case Rep Psychiatry 2014, 561092, https://doi.org/10.1155/2014/561092 (2014).

38. Heath, R. G., Nesselhof, W. Jr., Bishop, M. P. & Byers, L. W. Behavioral and Metabolic Changes Associated with Administration of Tetraethylthiuram Disulfide (Antabuse). Dis Nerv Syst 26, 99–105 (1965).

39. Payne, R. W., Carpenter, G. & Kessel, N. Effect of antabuse on intellectual and metabolic changes associated with administration of disulfiram to patients with chronic alcoholism. Dis Nerv Syst 34, 655–658 (1965).

40. Prigatano, G. P. Neuropsychological functioning of recidivist alcoholics treated with disulfiram: a follow-up report. Int J Addict 15, 287–294 (1980).

41. Beeke, S. C. et al. Effect of disulfiram on cognition, subjective response, and cortical-event-related potentials in nonalcoholic subjects. Alcohol Clin Exp Res 3, 223–229 (1979).

42. Savolainen, K., Hervonen, H., Lehto, V. P. & Mattila, M. J. Neurotoxic effects of disulfiram on autonomic nervous system in rat. Acta Pharmacol Toxicol (Copenh) 55, 339–344 (1984).

43. Molinengo, L., Oggero, L., Ghi, P. & Orsetti, M. Action of a chronic disulfiram administration on memory decay and on central cholinergic and adrenergic systems. Brain Res 551, 72–77 (1991).

44. Schliebs, R. & Arendt, T. The cholinergic system in aging and neuronal degeneration. Behav Brain Res 221, 555–563, https://doi.org/10.1016/j.bbr.2011.10.058 (2011).

45. Ferreira-Vieira, T. H., Guimarães, I. M., Silva, F. R. & Ribeiro, F. M. Alzheimer’s disease: Targeting the Cholinergic System. Curr Neuropharmacol 14, 101–115 (2016).

46. Libe, C. A., Descamps, O., Zhang, Q., John, V. & Bredesen, D. E. Altering APP proteolyis: increasing sAPPalpha production by targeting dimerization of the APP ectodomain. PLoS One 7, e40027, https://doi.org/10.1371/journal.pone.0040027 (2012).
52. Nagai, N. & Ito, Y. Excessive hydrogen peroxide enhances the attachment of amyloid beta1-42 in the lens epithelium of UPL rats, a hereditary model for cataracts. *Toxicology* 315, 55–64, https://doi.org/10.1016/j.tox.2013.08.003 (2014).

53. Szegi, B. et al. Disulfiram Implantation for the Treatment of Alcoholism: Clinical Experiences from the Plastic Surgeon’s Point of View. *Arch Plast Surg.* 41, 571–575, https://doi.org/10.5999/aps.2014.41.3.571 (2014).

54. Wang, Z. et al. Poly lactic-co-glycolic acid controlled delivery of disulfiram to target liver cancer stem-like cells. *Nanomedicine* 13, e641–657, https://doi.org/10.1016/j.nano.2016.08.001 (2017).

55. Nagai, N., Mano, Y. & Ito, Y. An Ophthalmic Formulation of Disulfiram Nanoparticles Prolongs Drug Residence Time in Lens. *Biol Pharm Bull* 39, 1881–1887, https://doi.org/10.1248/bpb.b16-00592 (2016).

56. Endres, K. et al. Transnasal delivery of human A-beta peptides elicits impaired learning and memory performance in wild type mice. *BMC Neurosci* 17, 44, https://doi.org/10.1186/s12868-016-0280-9 (2016).

57. Reinhardt, S. et al. Unfolded protein response signaling by transcription factor XBP-1 regulates ADAM10 and is affected in Alzheimer’s disease. *FASEB J* 28, 978–997, https://doi.org/10.1096/fj.13-234864 (2014).

58. Steiner, H. et al. Glycine 384 is required for presenilin-1 function and is conserved in bacterial polytopic aspartyl proteases. *Nat Cell Biol* 2, 848–851, https://doi.org/10.1038/35041097 (2000).

59. Deacon, R. M. Assessing nest building in mice. *Nat Protoc* 1, 1117–1119, https://doi.org/10.1038/nprot.2006.170 (2006).

60. Schneider, C. A., Rasband, W. S. & Eliceiri, K. W. NIH Image to ImageJ: 25 years of image analysis. *Nat Methods* 9, 671–675 (2012).

**Acknowledgements**

We thank Danuta Weichert (SPE, Mainz) for excellent support during the clinical study and all patients, their caregivers, and the healthy controls for participating. We also are thankful for C. Braun’s (IHC Core facility of the University Medical Center Mainz) help with brain slides and IHC. Jacqueline Trotter supplied valuable support by critically reading the manuscript (Institute of Developmental Biology and Neurobiology, Johannes Gutenberg University of Mainz).

**Author Contributions**

K.E., K.L. and S.R. designed the research. N.S. and U.S. performed the animal behavioral experiments. S.R. performed cell culture experiments, K.E. conducted A-beta ELISAs and ADAM10 activity assays. N.S. performed qPCR analysis of Bace-1 and cell culture experiments regarding sAPP-beta, BACE-1, and TACE. M.L. and F.K. were in charge of the clinical study in the CIMH. All authors contributed to the interpretation and discussion of the data and participated in the preparation of the manuscript.

**Additional Information**

**Supplementary information** accompanies this paper at https://doi.org/10.1038/s41598-018-19577-7.

**Competing Interests:** The authors declare that they have no competing interests.

**Publisher’s note:** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. 

© The Author(s) 2018